Patent application number | Description | Published |
20090062275 | N-Substituted Imidazopyridine c-Kit Inhibitors - Compounds represented by Formula (I): | 03-05-2009 |
20090118499 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 05-07-2009 |
20090197864 | Furo- and Thieno [3,2-c] Pyridines - Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. | 08-06-2009 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 12-31-2009 |
20110136764 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS - Compounds of Formula 1, as shown below and defined herein: | 06-09-2011 |
20110224191 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines - Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. | 09-15-2011 |
20110281888 | Fused Bicyclic Kinase Inhibitors - Compounds of Formula I, as shown below and defined herein: | 11-17-2011 |
20120046267 | 7-AMINOFUROPYRIDINE DERIVATIVES - Compounds of Formula 1, as shown below and defined herein: | 02-23-2012 |
20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
20120196847 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 08-02-2012 |
20120329826 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by RON and/or MET. | 12-27-2012 |
20130072495 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1R, or ALK. This Abstract is not limiting of the invention. | 03-21-2013 |
20130190496 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 07-25-2013 |
20130231306 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS - Compounds of Formula 1, as shown below and defined herein: | 09-05-2013 |
20130253197 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: | 09-26-2013 |
20140315911 | DIHYDROPTERIDINONES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention. | 10-23-2014 |